Seer (NASDAQ:SEER - Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Seer to post earnings of ($0.31) per share for the quarter. Seer has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.
Seer (NASDAQ:SEER - Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.07. Seer had a negative return on equity of 20.87% and a negative net margin of 517.84%. The business had revenue of $4.44 million for the quarter, compared to analysts' expectations of $4.24 million. On average, analysts expect Seer to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Seer Trading Up 1.9 %
SEER traded up $0.04 on Wednesday, hitting $2.12. 444,392 shares of the company were exchanged, compared to its average volume of 475,442. The firm has a 50-day moving average price of $1.83 and a two-hundred day moving average price of $1.77. Seer has a twelve month low of $1.46 and a twelve month high of $5.65. The company has a market cap of $137.32 million, a price-to-earnings ratio of -1.56 and a beta of 1.65.
Insider Buying and Selling at Seer
In other Seer news, CEO Omid Farokhzad sold 52,857 shares of the firm's stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $2.03, for a total value of $107,299.71. Following the sale, the chief executive officer now directly owns 1,436,285 shares in the company, valued at $2,915,658.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 69,149 shares of company stock valued at $133,366. Insiders own 15.02% of the company's stock.
Wall Street Analyst Weigh In
Separately, Morgan Stanley reissued an "equal weight" rating and set a $7.00 price objective on shares of Seer in a research report on Tuesday, March 5th.
View Our Latest Analysis on SEER
About Seer
(
Get Free Report)
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Featured Stories
Before you consider Seer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seer wasn't on the list.
While Seer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
